Bioxodes

the company’s lead programme, ir-cpi, is the first in a novel class of antithrombotics, and is being developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. thanks to a novel mechanism of action, ir-cpi is potentially the world’s first injectable antithrombotic which can be used in all patient groups without causing high levels of bleeding and potentially without needing to be reversed or washed out at the end of critical procedures.